In the relentless pursuit of defying the aging process, NMN (Nicotinamide Mononucleotide) supplements have emerged as a beacon of hope, backed by compelling scientific evidence elucidating their potential efficacy in counteracting age-related decline.

Can NMN slow aging?

NMN raises cellular NAD+ and reactivates sirtuins whose activity falls with age. Human RCTs show measurable improvements in NAD+ level, gait speed, and skin outcomes over 8-12 weeks (Yoshino 2021) and (Miyawaki 2023). Whether this translates to lifespan extension in humans has not been proven and would require decades to demonstrate. NMN restores a cellular factor whose decline is associated with age-related dysfunction.

Understanding NMN and Cellular Health

At the core of NMN's anti-aging prowess lies its role as a precursor to NAD+ (nicotinamide adenine dinucleotide), a crucial coenzyme involved in numerous cellular processes. NAD+ plays a pivotal role in energy metabolism, DNA repair, and gene expression. However, as we age, NAD+ levels decline, leading to compromised cellular function and the onset of age-related ailments.

The Mechanism of Action

 

NMN supplementation through supplements like VaraSpan® offers a promising strategy to replenish NAD+ levels and restore cellular function. Once ingested, NMN is swiftly converted into NAD+ within cells, thereby enhancing cellular energy production and facilitating vital biological processes. This restoration of NAD+ levels has been shown to confer numerous health benefits, including improved mitochondrial function, enhanced DNA repair, and bolstered immune response.

Scientific Evidence

The efficacy of NMN supplements in combating age-related decline is underscored by a growing body of scientific research. Notably, a study published in Cell Metabolism demonstrated that NMN administration effectively ameliorated age-related physiological decline in mice, leading to improvements in insulin sensitivity, muscle function, and overall health (Yoshino et al., 2011). These findings provide compelling evidence for the potential translational benefits of NMN in humans.

Metabolic Health

One of the key areas of focus in human trials has been the impact of NMN supplementation on metabolic health. Initial results indicate that NMN may contribute to improvements in metabolic parameters such as insulin sensitivity, glucose metabolism, and lipid profiles. These findings suggest that NMN supplementation could play a vital role in managing metabolic disorders and promoting metabolic wellness.

Cognitive Function

Emerging evidence also suggests that NMN supplementation (through supplements like VaraSpan®) may have beneficial effects on cognitive function. Preliminary studies have shown that NMN has the potential to enhance cognitive performance, including memory, learning, and executive function. These findings raise exciting possibilities for the use of NMN as a cognitive enhancer and neuroprotective agent.

Overall Well-being

Beyond specific health outcomes, NMN supplementation has been associated with improvements in overall well-being and quality of life. Participants in human trials have reported subjective benefits such as increased energy levels, improved mood, and enhanced physical resilience. These subjective experiences align with objective measures of health and vitality, underscoring the holistic benefits of NMN supplementation.

Conclusion

Varalife® is on a quest to extend human longevity. Our 5-in-1 NMN Supplement VaraSpan® helps increase NAD+ levels from Day 1 itself. VaraSpan® is a revolutionary Anti-Aging formulation with ingredients backed by experts from Harvard Medical School and Stanford University. 

References

• Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), 528–536. https://doi.org/10.1016/j.cmet.2011.08.014
• ClinicalTrials.gov. (n.d.). Study of Nicotinamide Mononucleotide (NMN) on Metabolism. Identifier NCT03151239. https://clinicaltrials.gov/ct2/show/NCT03151239